INTRA-CELLULAR THERAPIES INC. - COMMON STOCK

Intra-Cellular Therapies Announces FDA Acceptance of CAPLYTA® (lumateperone) sNDAs for the Treatment of Bipolar Depression

03 May 2021 07:30:00 By Nasdaq GlobeNewswire

Intra-Cellular Therapies Announces Investor Webcast and Presentations on Lumateperone Programs at the Upcoming American Psychiatric Association (APA) Annual Meeting

22 Apr 2021 07:30:00 By Nasdaq GlobeNewswire

Intra-Cellular Therapies Announces Board of Director Nominations in Advance of 2021 Annual Meeting

20 Apr 2021 07:00:00 By Nasdaq GlobeNewswire

Intra-Cellular Therapies Presents Data on Antitumor Effects of Phosphodiesterase I Inhibition in a Preclinical Colorectal Cancer Model at the 2021 American Association for Cancer Research (AACR) Annual Meeting

12 Apr 2021 07:30:00 By Nasdaq GlobeNewswire

Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2020 Financial Results And Provides Corporate Update

25 Feb 2021 07:30:00 By Nasdaq GlobeNewswire

Intra-Cellular Therapies Announces Expansion of its Pipeline with the Introduction of a New Molecular Entity, ITI-1284

24 Feb 2021 07:30:00 By Nasdaq GlobeNewswire

Intra-Cellular Therapies to Present at the SVB Leerink 10th Annual Global Healthcare Conference

19 Feb 2021 08:00:00 By Nasdaq GlobeNewswire

Intra-Cellular Therapies to Host Fourth Quarter and Full-Year 2020 Financial Results Conference Call and Webcast

17 Feb 2021 08:00:02 By Nasdaq GlobeNewswire

CAPLYTA® (lumateperone) Open-Label Safety Switching Study in Patients with Schizophrenia Published in the Journal, Schizophrenia Research

21 Jan 2021 08:00:00 By Nasdaq GlobeNewswire

Intra-Cellular Therapies to Present at the 39th Annual J.P. Morgan Healthcare Conference

05 Jan 2021 08:00:00 By Nasdaq GlobeNewswire